UNAIR Inactivated COVID-19 Vaccine

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

495

Participants

Timeline

Start Date

February 8, 2022

Primary Completion Date

April 6, 2023

Study Completion Date

July 6, 2023

Conditions
COVID-19 PandemicVaccine Reaction
Interventions
BIOLOGICAL

UNAIR Inactivated COVID-19 Vaccine

UNAIR Inactivated Covid-19 Vaccine contains S protein of SARS-CoV-2 virus, Aluminium hydroxide gel, 10 mM L-Histidine buffer, 0.005% Tween Polysorbate 80, and 0.9% Sodium chloride. Vaccine will be prepared in vial (1 ml per vial). One vial will be used for one injection only. The vial should be shaken well before injection.

BIOLOGICAL

CoronaVac Biofarma COVID-19 Vaccine

Control vaccine in this study is existing CoronaVac-BioFarma inactivated COVID-19 vaccine which has been used widely in Indonesia.

Trial Locations (1)

67161

RECRUITING

Dr. Soetomo General Hospital, Surabaya

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Indonesia-MoH

OTHER_GOV

collaborator

Universitas Airlangga

OTHER

collaborator

Bioxis Pharmaceuticalls

INDUSTRY

lead

Dr. Soetomo General Hospital

OTHER_GOV